Journal
ADVANCED SCIENCE
Volume 10, Issue 6, Pages -Publisher
WILEY
DOI: 10.1002/advs.202204842
Keywords
dendritic cells maturation; mace-like gold-palladium heterostructures; photoimmunotherapy; PD-L1 blockade therapy; three negative breast cancer (TNBC)
Ask authors/readers for more resources
Photoimmunotherapy is a novel targeted therapeutic strategy for highly malignant triple-negative breast cancer. However, its therapeutic effect is restricted by limited tissue penetration of light and complex immunosuppressive microenvironment. A new mace-like plasmonic Au-Pd heterostructures have been developed to enhance the outcomes of photoimmunotherapy. These structures exhibit strong photothermal and photodynamic effects, triggering immunogenic cell death and stimulating immune response. This study integrates nanotopology and plasmonic performance for the treatment of TNBC through immunotherapy.
Photoimmunotherapy, with spatiotemporal precision and noninvasive property, has provided a novel targeted therapeutic strategy for highly malignant triple-negative breast cancer (TNBC). However, their therapeutic effect is severely restricted by the insufficient generation of tumor antigens and the weak activation of immune response, which is caused by the limited tissue penetration of light and complex immunosuppressive microenvironment. To improve the outcomes, herein, mace-like plasmonic Au-Pd heterostructures (Au Pd HSs) have been fabricated to boost near-infrared (NIR) photoimmunotherapy. The plasmonic Au Pd HSs exhibit strong photothermal and photodynamic effects under NIR light irradiation, effectively triggering immunogenic cell death (ICD) to activate the immune response. Meanwhile, the spiky surface of Au Pd HSs can also stimulate the maturation of DCs to present these antigens, amplifying the immune response. Ultimately, combining with anti-programmed death-ligand 1 (alpha-PD-L1) will further reverse the immunosuppressive microenvironment and enhance the infiltration of cytotoxic T lymphocytes (CTLs), not only eradicating primary TNBC but also completely inhibiting mimetic metastatic TNBC. Overall, the current study opens a new path for the treatment of TNBC through immunotherapy by integrating nanotopology and plasmonic performance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available